Polyrizon reports positive preclinical results for its intranasal drug delivery platform, showing effective CNS drug targeting in nasal cavities.
Quiver AI Summary
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in collaboration with the University of Parma. The study demonstrated that the hydrogel formulation targets key areas in the nasal cavity, achieving over 60% accumulation in regions suitable for central nervous system (CNS) drug delivery, which could be beneficial for treating conditions like opioid overdose and seizures. CEO Tomer Izraeli highlighted the important implications of this localized delivery for acute neurological and psychiatric therapies. Polyrizon plans to validate these findings through further preclinical studies and safety assessments in animal models as part of their development strategy for the T&T technology.
Potential Positives
- Polyrizon announced promising preclinical results from its T&T platform, demonstrating effective targeted drug delivery to the critical regions of the nasal cavity for potential CNS treatments.
- The study was conducted in collaboration with the University of Parma and was led by a recognized expert, enhancing credibility to the research and the technology.
- The hydrogel platform's ability to achieve over 60% preferential accumulation in favorable anatomical regions supports its potential use in rapid-response scenarios for CNS-related conditions, which could significantly impact patient care.
- Polyrizon plans to validate its findings in animal models and initiate safety studies, indicating a strategic roadmap focused on advancing its novel intranasal drug delivery systems toward clinical applications.
Potential Negatives
- The press release relies heavily on forward-looking statements, which inherently carry significant risks and uncertainties that could lead to actual outcomes differing materially from expectations.
- The company is still in the preclinical development stage, meaning there is no guarantee that the promising results will translate into successful therapies or products.
- The potential applications mentioned for the hydrogel technology (e.g., treating opioid overdose and epilepsy) indicate high-stakes situations, which could result in increased scrutiny and pressure for the company to deliver effective solutions.
FAQ
What are Polyrizon's recent study results?
Polyrizon announced encouraging preclinical results showing targeted drug delivery in the nasal cavity using its T&T hydrogel platform.
How does the Trap & Target technology work?
The T&T technology utilizes a proprietary hydrogel for targeted deposition in the nasal cavity, enhancing drug delivery to the CNS.
Who collaborated with Polyrizon on the recent study?
The study was conducted in collaboration with the University of Parma, led by Professor Fabio Sonvico.
What potential benefits does this research offer for drug delivery?
This technology could improve treatment for CNS conditions by providing rapid access to the brain for critical medications.
What is Polyrizon's focus moving forward?
Polyrizon plans to validate its findings in animal models and initiate safety studies for their T&T technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon’s hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery.
The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the University of Parma (Italy), led and conducted by Professor Fabio Sonvico, a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.
Using a silicone-based human nasal cast and fluorescein-traced imaging, the Polyrizon hydrogel formulation was shown to exhibit a preferential accumulation of over 60% in the middle and upper turbinates, the region’s most favorable for nose-to-brain transport. This region-specific delivery has the potential to be particularly promising for CNS indications, such as opioid overdose (e.g., naloxone) and benzodiazepine for epileptic seizures, where rapid and direct access to the brain can be lifesaving.
“The results validate the unique capabilities of our T&T technology in achieving localized deposition in anatomically favorable zones of the nasal cavity,” said Tomer Izraeli, CEO at Polyrizon. “We believe that this has the potential to open a strategic path forward for leveraging our intranasal platform in the development of therapies for acute neurological and psychiatric conditions.”
Polyrizon’s hydrogel demonstrated consistent, concentrated delivery to the upper nasal segments while maintaining favorable handling characteristics. These findings support the continued preclinical development of the T&T platform for CNS-targeted applications.
Polyrizon intends to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit
https://polyrizon-biotech.com
.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its Trap and Target™ (T&T) platform has the potential to opens a strategic path forward for leveraging its intranasal platform in the development of therapies for acute neurological and psychiatric conditions, the continued preclinical development of the T&T platform for CNS-targeted applications and its intention to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
